| frequently downregulated miR-217 can regulate KRAS and function as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC). | pancreatic, |
| miR-217 plays a tumor suppressor role in clear cell renal cell carcinoma | kidney, |
| findings suggest miR-217 function as a potential tumor suppressor in HCC progression and miR-217-E2F3 axis may be a novel candidate for developing rational therapeutic strategies | liver, |
| miR-217 may act as a tumor suppressor in osteosarcoma. | osteosarcoma, |
| miR-217 functions as a tumor suppressor in osteosarcoma by suppressing Wnt5a expression. | osteosarcoma, |
| miR-217 functioned as a tumor suppressor and inhibited the proliferation and invasion of Gastric cancer cells by targeting GPC5 | gastric, |
| these results demonstrated that miR-217 plays a tumor suppressor role in human epithelial ovarian cancer by directly targeting IGF1R gene, suggesting a new potential therapeutic target in epithelial ovarian cancer . | ovarian, |
| Abnormal expression of hsa-miR-96 and of hsa-miR-217 was observed in premalignant lesions (PanINs and IPMNs) of pancreatic carcinoma and down-regulated with increasing grades of PanINs and IPMNs. These microRNAs may serve as potentially early biomarker and act as tumor suppressor genes | pancreatic, |
| The data demonstrated a tumor suppressor role for miR-217 in thyroid cancer development and progression by targeting AKT3 | thyroid, |
| MicroRNA-217 functions as a tumor suppressor in cervical cancer cells through targeting Rho-associated protein kinase 1 | cervical, |
| our data provide solid evidence that miR-217 functions as tumor suppressor in osteosarcoma, and its tumor-suppressive effect is exerted through interaction with SETD8. | osteosarcoma, |
| MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin | cervical, |